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Abstract
Background: The burden of stroke is high and increasing in China. We modelled variations in, and predictors of, the costs of
hospital care for patients with acute stroke in China.
Methods and Findings: Baseline characteristics and hospital costs for 5,255 patients were collected using the prospective
register-based ChinaQUEST study, conducted in 48 Level 3 and 14 Level 2 hospitals in China during 2006–2007. Ordinary
least squares estimation was used to determine factors associated with hospital costs. Overall mean cost of hospitalisation
was 11,216 Chinese Yuan Renminbi (CNY) (<US$1,602) per patient, which equates to more than half the average annual
wage in China. Variations in cost were largely attributable to stroke severity and length of hospital stay (LOS). Model
forecasts showed that reducing LOS from the mean of 20 days for Level 3 and 18 days for Level 2 hospitals to a duration of 1
week, which is common among Western countries, afforded cost reductions of 49% and 19%, respectively. Other lesser
determinants varied by hospital level: in Level 3 hospitals, health insurance and the occurrence of in-hospital complications
were each associated with 10% and 18% increases in cost, respectively, whilst treatment in a teaching hospital was
associated with approximately 39% decrease in cost on average. For Level 2 hospitals, stroke due to intracerebral
haemorrhage was associated with a 19% greater cost than for ischaemic stroke.
Conclusions: Changes to hospital policies to standardise resource use and reduce the variation in LOS could attenuate costs
and improve efficiencies for acute stroke management in China. The success of these strategies will be enhanced by broader
policy initiatives currently underway to reform hospital reimbursement systems.
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Introduction
In China, the world’s most populous country, stroke is an
enormous health care burden, representing the second leading
cause of death and occurring in approximately 2 million people
each year [1]. In light of demographic shifts towards an older and
more urbanised population, and the limited available treatment
and prevention strategies, the high costs of stroke care are
projected to rise in China.
Two key dimensions to the economic burden of major chronic
diseases such as stroke, in many developing countries such as
China are: the lack of universal health insurance coverage so that
significant cost impacts are borne directly by patients and their
families [2]; and increasing health care costs associated with
investigations, medications and treatment. These factors, com-
pounded by uncertainties over the overall costs of treatment at the
onset of illness, are likely to impair access to timely care. Recent
efforts to expand the coverage of social health insurance to urban
and rural regions in China, has great potential to encourage access
to care and reduce the economic impact of illness and, despite
some early mixed results [3–6], appears to be producing positive
outcomes [7]. Another initiative, case-based hospital funding that
was introduced in 2007, is expected to promote uniformity in the
costs of hospital care, with 22% of Chinese hospitals already
adopting this method of payment [8].
A clear understanding of the drivers of variations in health care
costs is instrumental to developing and implementing policies
aimed at improving the efficiency of public expenditure. At
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been exacerbated by a reimbursement system that is essentially
fee-for-service and linked to provider remuneration which in turn
can create incentives for unnecessary care [9–11]. However,
proposed pilot studies of innovative provider payment systems
offer promising mechanisms to address this problem [10].
Although data on the economic aspects of stroke using a mix of
prevalence and incidence based approaches are widely available
[12–17], the few studies undertaken in China [18–21] have been
restricted in location and the assessment of costs, thereby limiting
their ability to capture the full range of variation and key
determinants of costs. We aimed to examine factors associated
with variation in the hospital costs of stroke by including data from
hospitals in varied geographical and socioeconomic regions of
China.
Methods
Ethics statement
The study was approved by the ethics committees of Peking
University First Hospital (Beijing), Ruijin Hospital (Shanghai),
Prince of Wales Hospital (Hong Kong), and The University of
Sydney. Good Clinical Practice guidelines in accordance with the
Declaration of Helsinki were used, and the privacy of patients was
strictly protected.
Study design
The ChinaQUEST (QUality Evaluation of Stroke Care and
Treatment) study used a prospective, national, multi-centre,
hospital-based register to collect data on patients admitted to
hospital with acute stroke across mainland China over a 5-month
period in 2006. Chinese hospitals are classified as Level 1
(community hospitals with only the most basic facilities and very
limited inpatient capacity), Level 2 (hospitals with at least 100
inpatient beds providing acute medical care and preventative care
services to populations of at least 100,000), and Level 3 (major
tertiary referral centres in provincial capitals and major cities). Of
the 70 Level 2 and 3 hospitals that were invited to participate, 62
hospitals in 37 cities agreed and completed the study requirements,
as described in detail elsewhere [2]. Briefly, the study included
consecutive patients (age $15 years) with stroke due to cerebral
infarction (‘ischaemic stroke’) or intracerebral haemorrhage (ICH)
who agreed to 4 interview-based assessments at: baseline (after
admission), hospital discharge, and 3 and 12 months follow-up.
Written informed consent was obtained from all patients, or an
appropriate family member (in situations where the patient was
disabled) to participate.
Information on baseline sociodemographic situation was
obtained predominantly by face-to-face interviews, in-hospital
details were obtained through medical records and interviews with
patients or proxies, and follow-up details including health
expenditure were obtained primarily through telephone inter-
views. Baseline information collected included patient socio-
demographic characteristics, clinical features, and history of co-
morbid cardiovascular (CV) risk factors. Pathological stroke type,
diagnostic and management options employed in-hospital, and
various outcome measures of patients on discharge, were also
recorded. Data were transferred to electronic Case Record Forms
on a secure website connected to a central, password-protected,
database located at The George Institute for Global Health in
Sydney, Australia. Lead investigators at participating hospitals
were also asked to complete a site questionnaire detailing specific
hospital information and unit costs of medications, investigations,
procedures, and ward costs, at their hospital to ascertain a list of
itemised cost for their facility.
Explanatory and outcome variables
All the costs of in-hospital care for stroke (N=5,255) were
obtained from patients (or proxies) who were asked to estimate
their overall expenditure for hospital treatment at the time of the 3
month follow-up assessment. As patients are generally given an
invoice of itemised hospital costs at the time of hospital discharge,
these data were expected to be well recorded and to provide a
reliable outcome measure. The following covariates were included
a priori in multivariate models based on evidence of their
associations with hospital utilisation: age [22], gender [23–24],
marital status [25], living alone [26], owns health insurance [19],
CV risk [19,22,25], pathological stroke type [24,27], severe
Glasgow Coma Scale (GCS) score on admission (defined as 3–8
of a top score of 15) [22,28–29], received assisted feeding in-
hospital [30], experienced any in-hospital complication [19,24],
length of hospital stay (LOS) [19,22], and hospital characteristics
[23] including size, teaching status and location. Annual
household income was also included as a covariate, given the
likely association with health insurance. In addition, disability/
dependency on discharge (defined by a modified Rankin Scale
[mRS] score of 3–5) was also included to account for stroke
severity on recovery.
CV risk was modelled as a continuous measure, graded from 0
to 10 according to the number of CV co-morbid risk factors
present, based either on: (i) responses to questions about prior
history ‘‘Before this stroke, was the patient ever told they have any
of the following: high blood pressure, a previous stroke, diabetes
mellitus, high cholesterol/lipids, atrial fibrillation (AF), previous
TIA (transient ischaemic attack), heart attack/myocardial infarc-
tion, angina/coronary heart disease’’, or: (ii) new diagnoses of AF,
coronary heart disease, hypertension, diabetes mellitus, and
hyperlipidaemia/elevated cholesterol (including patients with total
cholesterol level $5.20 mmol/L on discharge [31]) reported post-
stroke in-hospital. Cigarette smoking, regular alcohol consumption
within the 3 months before the stroke, and being overweight
(based on a body mass index $24 kg/m
2 [31]) were also included
in the CV risk assessment. In-hospital complication was defined as
pneumonia, deep venous thrombosis, recurrent stroke, urinary
tract infection, other sepsis, pulmonary embolus, coronary event,
seizure, fall with injury, or any other clinically significant event
that prolonged hospital stay. Location of the hospital was
considered according to: (i) economic factors, with the 2006 per
capita Gross Regional Product (GRP) for the province in which
the hospital is located and; (ii) geography, with hospitals segregated
into ‘northern’ (includes the areas of Beijing, Hebei, Heilongjiang,
Henan, Inner Mongolia, Jilin, Liaoning, Qinghai, Shaanxi,
Shandong, Tianjing, and Xinjiang) and ‘southern’ (includes the
areas of Anhui, Chongqing, Fujian, Guangdong, Guangxi, Hubei,
Hunan, Jiangsu, Jiangxi, Shanghai, Sichuan and Yunnan
province).
Statistical analyses
Data excluded from these analyses were those from patients
(n=50) registered in Hong Kong due to the city having different
economic and healthcare patterns to mainland China. Signifi-
cance of baseline differences between included and excluded
patients, were assessed using x
2 test for categorical variables, t test
for continuous normally distributed variables, and Mann
Whitney U test for continuous skewed variables. To account for
non-negativity and positively skewed empirical distribution of
Cost of Acute Stroke in China
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including ordinary least squares (OLS) and generalised linear
models (GLM) with log links: GLM models generally produce
more consistent models albeit with imprecise estimates if the log-
scale error is heavy-tailed; whilst OLS models can be biased and
inefficient when heteroskedasticity exists [32–33]. In these
analyses, the log-scale residuals from the GLM models were
heavily-tailed (coefficient of kurtosis .20 regardless of the specific
GLM model used, c Gaussian or Poisson) and there was no
evidence of heteroskedasticity in the OLS model whether assessed
visually or by using Koenker’s N*R2 version of the score test
(which does not assume normally distributed errors). Thus, we
initially selected the OLS model based on the Manning and
Mullahy checklist [32]. In addition, although a random effects
model estimated using feasible generalised least squares may have
been more efficient, the Hausman specification test was violated,
so a random effects model would have produced biased
estimators [34]. Therefore, for this study, OLS regression analysis
was conducted to determine factors associated with in-hospital
cost (converted to US$100 to facilitate interpretation of
coefficients) with prior log transformation of model outcome
due to skewed raw data. Furthermore, to account for clustering of
patients at the hospital level, clustered standard errors were
estimated [33]. Age, number of CV risk factors, GRP and log
transformed LOS were included as continuous variables. Checks
were made of all plausible interactions and collinearity between
variables. Collinearity was assessed by examination of bivariate
scatterplots, correlation matrix, mean and individual variance
inflation factors, and conditional numbers. As collinearity was
detected between the level and size of hospitals, models were
developed separately for Level 2 and 3 hospitals. All significant
interactions were initially identified. Backward stepwise approach
was then used to successively remove non-significant interactions
in the full models.
Sensitivity analyses were conducted to examine the effect of: (i)
excluding patients with any re-admission after the initial hospital
stay; and (ii) imputing by chained equations [35] missing values of
cost, LOS, and GCS and mRS scores using model covariates as
well as the following auxiliary variables: education level;
employment status; occupation type; prior dependency; Oxford-
shire Community Stroke Project classification of stroke; death by 3
months post-stroke; time from symptom onset to hospital
presentation (log transformed); use of the following intravenous
therapies in hospital: thrombolysis, corticosteroid, haemodiluting
agents (such as mannitol), neuroprotectants (including edaravone,
ganglioside GM1, cattle encephalon glycoside and ignotin,
cinepazide, citicholine), traditional Chinese medicine (TCM,
alternative/herbal medicine); and use of antihypertensive, anti-
platelet and lipid lowering therapies in-hospital and during the 3
months post-stroke.
In addition, to determine the full extent of the effect of
modifiable variables on cost, their marginal effects by hospital level
and stroke type (i.e. holding all other variables constant at their
means) were calculated from coefficients derived from the model.
As residual variance was not normally distributed but homo-
skedastic, Duan’s non-parametric retransformation [36] factor
(1.24 for Level 3 hospitals, 1.25 for Level 2 hospitals) was used in
the evaluation of the marginal effects. Moreover, one-way analysis
of variance (ANOVA) was performed to determine the proportion
of variance associated with differences in cost amongst hospitals by
hospital level. Itemised costs were based on investigator provided
hospital data. Statistical significance was considered at p,0.05. All
analyses were conducted using STATA 10.1 (StataCorp LP,
College Station, TX).
Results
Figure 1 shows the flow of patients. Of 6,416 patients with
baseline data, 1,161 were excluded due to death and no cost data
(n=668), or missing data and a priori exclusion criteria (n=493).
Thus, there were 5,255 patients with complete data for analyses.
Compared with patients excluded due to death and no cost data,
those included in analyses were more likely to be younger,
married, have health insurance, higher incomes, stroke due to
lacunar infarction, longer LOS, and to be managed in large Level
3 hospitals. In addition, fewer included patients had ICH, large
artery cerebral infarcts, severe GCS score on admission, in-
hospital assisted feeding and complications, and death/disability at
discharge (Table S1). Separate comparison of the included patients
with those excluded for reasons other than death (n=493) showed
similar distributions of age, gender, CV risk profile, initial severity,
in-hospital assisted feeding/complications, LOS, disability on
discharge, and geographical location of admitting hospital.
However, included patients were more likely to be married, not
living alone, not insured for health, a low income earner, an ICH
patient, surviving after hospital discharge, to have lower CV risk,
and to have been managed in a Level 2 non-teaching hospital in a
low GRP area (data available on request).
Table 1 shows the costs of selected common investigations,
treatments and wards for patients with stroke, based on hospital
supplied itemised costs. The highest reported costs were for
magnetic resonance imaging (MRI) with contrast media, intrave-
nous tissue plasminogen activator (tPA), intravenous neuroprotec-
tant ganglioside GM1, and care in an intensive care unit (ICU). As
shown by the high coefficients of variation, the greatest variations
in cost between hospitals were for the use of calcium channel
blockers and ICU stay in Level 3 hospitals, and defibrase and
TCM in Level 2 hospitals.
Overall average LOS was 20 days (median 17, interquartile
range 12–25), but varied by hospital level (Level 3 20 days, Level 2
18 days) and stroke type (ischaemic stroke 19 days, ICH 23 days).
The mean cost of acute stroke care was 11,216 CNY (<US$1,602)
per patient, but this figure differed widely by the location and level
of hospital (Figure 2), and was lower for ischaemic stroke (10,689
Figure 1. Patient flow.
doi:10.1371/journal.pone.0013041.g001
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daily cost of stroke was 565 CNY (<US$81) per person overall
(based on mean LOS), and was 565 CNY (<US$81) and 564
CNY (<US$81) per person for ischaemic stroke and ICH,
respectively. In addition, cost varied by LOS: median average
bed day cost was CNY 2,883 (<US$412) for patients who stayed
#3 days in hospital and CNY 333 (<US$48) for patients with
LOS of .4 weeks (Figure 3).
Multivariate regression analysis showed that factors significantly
associated with increased cost of acute stroke care for Level 3
hospitals included: younger age, being married, having health
insurance, higher household income, stroke due to large artery
cerebral infarction, greater initial stroke severity, need for assisted
feeding, presence of in-hospital complications, long LOS, being
disabled/dependent on discharge, and being treated in a large
hospital in a rich province (Table 2). Notably, having health
insurance, high annual household income ($20,000 CNY
[<US$2,857]), a large artery cerebral infarction, and in-hospital
complication(s) were each associated with 10%, 30%, 11%, and
18% increases in cost, respectively. Similarly, for Level 2 hospitals,
marital status, assisted feeding, LOS, and disability on discharge,
were associated with increased costs. In addition, ICH was
associated with a 19% increase in cost. Model forecasts further
illustrate the impact of these variables on cost, in particular for
LOS, where reduction to a fixed LOS of 1 week, that is typical for
stroke in hospitals of Western countries, affords approximately
49% and 19% reductions in costs for Level 3 and 2 hospitals,
respectively (Table 3). Finally, 8% and 19% of the variation in cost
in Level 3 and Level 2 hospitals, respectively, were attributable to
inter-hospital differences.
Sensitivity analyses excluding those with hospital re-admission(s)
post-discharge (n=526) showed that health insurance, income,
LOS and hospital characteristics remained unchanged as the key
drivers of cost. For Level 2 hospitals, the main effects remained
essentially unchanged following exclusion of those patients with
hospital re-admissions; however the interaction between health
insurance and income became non-significant. Sensitivity analyses
using multiple imputations to account for biases that may have
Table 1. Average cost of selected investigations, treatments, and wards, by hospital level in China.
Level 3 hospital (N=45) Level 2 hospital (N=14)
Mean (Median) CNY Cv* Mean (Median) CNY Cv*
Investigations (by single test)
Computerised tomography, brain (no contrast) 262 (250) 0.41 195 (180) 0.29
Magnetic resonance imaging, brain (+ contrast) 1053 (1035) 0.29 750 (730) 0.54
Electrocardiogram 23 (20) 0.43 19 (20) 0.34
Doppler ultrasound of carotids 172 (170) 0.32 158 (140) 0.50
Transthoracic echocardiogram 191 (200) 0.45 174 (200) 0.24
Transcranial doppler ultrasound 132 (120) 0.41 93 (94) 0.43
Treatments – intravenous (by ampoule)
tPA (tissue plasminogen activator) 5226 (6283) 0.53 7843 (7843) 0.21
Urokinase 248 (230) 0.80 279 (220) 0.78
Defibrase 315 (314) 0.61 273 (80) 1.84
Mannitol 11 (6) 1.66 5 (4) 0.36
Neuroprotectants
Edaravone 211 (210) 0.46 289 (237) 0.34
Ganglioside GM1 465 (340) 0.78 373 (160) 0.99
Cattle encephalon glycoside & ignotin 186 (200) 0.59 262 (99) 1.38
Cinepazide maleate 129 (116) 0.48 74 (67) 0.38
Citicholine 8 (4) 1.30 5 (4) 0.50
Traditional Chinese medicine 66 (59) 0.66 52 (46) 0.75
Treatments – oral (by tablet)
Beta blocker 2 (1) 2.27 1 (1) 0.69
Calcium channel blocker 7 (3) 3.89 2 (1) 1.05
Angiotensin-converting enzyme inhibitor 3 (2) 1.50 1 (1) 1.24
Clopidogrel 22 (21) 0.48 19 (22) 0.25
Angiotensin II receptor blocker 6 (6) 0.48 5 (6) 0.50
Traditional Chinese medicine 7 (3) 1.25 11 (8) 1.42
Wards (per day)
General medical ward 44 (40) 0.55 35 (30) 0.60
Neurology ward 49 (38) 0.67 40 (32) 0.68
Intensive care unit 375 (200) 1.66 179 (140) 0.72
*Coefficient of variation, equal to the standard deviation divided by the mean; to convert CNY to US dollars, divide by 7.
doi:10.1371/journal.pone.0013041.t001
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that for Level 3 hospitals, results were unchanged apart from a few
interactions that became no longer significant. In analyses of
imputed data for Level 2 hospitals, marital status and the
interaction between insurance and income became non-signifi-
cant, while patients with severe GCS score on admission were
found to have increased costs.
Discussion
This large national health outcome study has documented the
various costs of hospital care that may be associated with an
episode of acute stroke in China. We estimated that, on average,
the overall hospital cost for stroke is 11,216 CNY (<US$1,602),
which equates to 565 CNY (<US$81) per day according to an
average LOS of nearly 3 weeks (20 days). Given a national average
annual wage of 21,001 CNY (<US$3,000) in 2006 [37], this
health care cost translates into more than half a year’s wage for
many people in China. These estimates are higher than the official
(mean hospital cost) figures from the Chinese Ministry of Health of
6,325 CNY for ischaemic stroke and 7,732 CNY for ICH [38].
This may have been due to many of the patients in our study
having long LOS, being included mainly from urban locations,
and for any hospital re-admission costs within the 3 month follow-
up period to have been included in the estimates. Even so, our cost
estimates are comparable with those reported in a 2 centre, single
city, study by Gao et al [21] in China, and in the findings of lower
costs for ischaemic stroke than ICH as has been shown in studies
from Greece [27], United States [39], Australia [40], and Japan
[41].
Variations in the cost of acute stroke tend to be driven by stroke
severity and hospital LOS, with patients with more severe
neurological impairment (lower GCS scores) on admission,
requiring assisted feeding, being more disabled (mRS) at
discharge, and having longer LOS, being more likely to incur
higher costs of care regardless of the level of hospital. In Level 3
hospitals, though, amount of household income and possession of
health insurance were also positive drivers of cost, suggesting the
potential for discriminatory pricing by socioeconomic status.
Another discrepancy noted between the varying hospital levels
was that in-hospital complications were predictive of cost variation
in Level 3 but not Level 2 hospitals, raising questions about the
potential higher risks of infectious and other complications in
larger hospitals that could impact on LOS, outcomes and costs.
Indeed, we found that Level 3 hospitals had a higher frequency of
infectious complications (including pneumonia, urinary tract
infection, sepsis) than Level 2 hospitals (13% vs. 6%). These
findings are analogous to previous studies in China which have
also reported LOS, health insurance status, infection during
hospital stay, and stroke severity, all being strongly associated with
increased total inpatient cost [18–21]. Conversely, a clear
explanation for why age was associated with reduced costs in
Level 3 hospitals but not Level 2 hospitals, is not readily
forthcoming. However, there may be differences in the type and
level of intervention (and care) being assigned to those patients
with a poor prognosis between these types of hospitals.
Figure 2. Mean total cost of stroke, by hospital type, location and 2006 per capita GRP. GRP, Gross Regional Product for the province.
doi:10.1371/journal.pone.0013041.g002
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variation in costs at either hospital level, which is consistent with a
recent study in Greece [27], but differs from Evers et al [24] who
found that females were more likely to experience higher costs
than males. Such comparisons between studies, however, are likely
confounded by differences in case-mix and patterns of care.
Moreover, ICH was not a predictor of cost variation in Level 3
hospitals, a finding which may be due to shorter LOS (and/or
more conservative management) for a condition which tends to
have a worse prognosis than ischaemic stroke. In addition, patients
with multiple CV co-morbidities/risk factors were not shown to be
subjected to higher cost, irrespective of hospital level, however, this
is consistent with the current literature where both significant and
null results have been reported for associations between CV co-
morbidities and hospital utilisation [22].
Our study also found that costs tended to be higher in large
Level 3 hospitals located in provinces with a high GRP. This may
be indicative of increased likelihood of severe and complex
patients being managed in larger tertiary referral hospitals, and
higher staff and infrastructure costs for hospitals in more affluent
provinces. Among the Level 3 hospitals, though, those with
teaching hospital status had markedly lower costs, which may
reflect educational and awareness activities to promote best
practice, evidence based guidelines and clinical care pathways.
In addition, reduced variation in cost between Level 3 hospitals
and Level 2 hospitals may reflect a higher proportion of teaching
hospitals in the former focussed on evidence based practice and
with less potential for discriminatory pricing.
Given that LOS is a main determinant of hospital costs, the
adoption of case based funding through the use of Diagnosis
Related Group (DRG) Prospective Payment Systems, as has been
implemented in the United States [42], Australia and other
countries, offers promise in reducing health care costs in China.
For example, an Australian study has shown that the direct and
indirect costs incurred during the first year after stroke (excluding
inpatient costs for the primary event and average LOS in hospital,
and where average LOS was about 1 week) were: on average,
Australian [AU] $19 per person per day for ischaemic stroke and
AU $28 for ICH; whereas, average daily hospital costs (calculated
from average LOS) were AU $490 and $702 for ischaemic stroke
and ICH, respectively [40]. In-hospital medication use, notably
the high use of non-evidence based therapies such as neuropro-
tectants (e.g. edaravone, ganglioside, etc) and TCM, may also
contribute to the burden of health costs in China, with previous
studies and national estimates revealing that more than half the
average cost of hospitalisation is composed of medication costs for
both ischaemic stroke and ICH [20–21,38]. The implementation
of clinical care pathways may assist in standardising care, thereby
reducing the use of non-evidence based therapy and minimising
variation in LOS in acute stroke [43].
We recognise our study has limitations that deserve comment.
Firstly, we were unable to examine the effect of other factors which
may have influenced hospital costs, including physician charac-
teristics and staff capacity. Secondly, our study was predisposed to
survivor bias, as cost estimates could only be obtained for a small
proportion of patients who had died. However, patients experi-
encing early death after stroke are likely to have lower costs due to
greater severity and/or co-morbidities, and shorter hospital LOS.
In addition, the characteristics of such patients were likely
captured to some extent amongst the cost driver (predictor)
variables included in the models. There is also the potential for
differential bias, as we only had costing data available for a small
number of patients who had died. However, sensitivity analyses
using multiple imputations showed minimal changes to our
estimates, so the effect of this bias is likely to be negligible.
Thirdly, we may have over-estimated the short-term cost savings
that could be derived from reducing average LOS in China, as
most of the costs of care are incurred within the first few days of
admission to hospital, as shown in Figure 3. Nonetheless, as stroke
is a severe disease and patients are often transferred from smaller
Figure 3. Box plots of average bed day cost by length of stay. CNY denotes Chinese Yuan Renminbi, with 7 CNY equating to one United
States dollar; the central line denotes the median, the box encompasses the 25
th and 75
th percentiles, and the whiskers denote the lower and upper
adjacent values as defined by Tukey [47].
doi:10.1371/journal.pone.0013041.g003
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seems reasonable to assume that our cost estimates are widely
applicable to patients with stroke in hospitals located in inner and
peripheral, urban areas. In addition, since patients with mild-to-
moderate levels of residual disability are likely to be discharged
home after having most investigations and acute treatments
completed within the first week of admission to hospital, the
ongoing costs of hospital care are likely to be driven principally by
those associated with a bed day stay. Nevertheless, efforts to
reduce LOS, through for example early supported discharge,
could provide the opportunity for greater service options for
patients (and providers) and the potential for improved health
Table 2. Factors associated with total cost of stroke in hospital in China*.
Predictor Level 3 hospital (N=4,120) Level 2 hospital (N=1,135)
Regression
coefficient
Standard
error P-value
Regression
coefficient Standard Error P-value
Sociodemographic
Age: per year 20.003 0.001 0.02 0.002 0.002 0.33
Female 0.019 0.021 0.37 20.030 0.048 0.54
Married 0.499 0.165 0.004 0.128 0.059 0.05
Living alone 20.032 0.065 0.63 20.037 0.117 0.75
Owns health insurance 0.106 0.048 0.03 20.082 0.076 0.30
Annual household income
{
10,000 – 19,999 CNY (< US$1,429–2857) 0.322 0.059 ,0.001 20.145 0.126 0.27
$20,000 CNY (< US$2,857) 0.362 0.084 ,0.001 0.249 0.134 0.09
Declined to respond/unknown 0.022 0.074 0.76 20.058 0.071 0.43
Medical/clinical features
Cardiovascular risk factors: per risk factor 0.007 0.008 0.37 0.025 0.021 0.26
Stroke type
{
Large artery cerebral infarct 0.113 0.053 0.04 20.065 0.068 0.36
Intracerebral haemorrhage 0.035 0.036 0.33 0.208 0.073 0.01
Other/uncertain 0.098 0.056 0.09 20.092 0.168 0.59
Severe GCS score on admission 0.158 0.064 0.02 0.198 0.097 0.06
Assisted feeding in-hospital 0.352 0.081 ,0.001 0.269 0.122 0.05
Outcome at discharge
Experienced $1 in-hospital complication 0.198 0.049 ,0.001 20.0300 0.073 0.69
Length of hospital stay
1 0.636 0.068 ,0.001 0.227 0.050 0.001
Disability/dependency 0.252 0.036 ,0.001 0.242 0.067 0.003
Hospital characteristics
Large size (.500 beds) 0.610 0.191 0.002 20.137 0.232 0.56
Teaching 20.502 0.09 ,0.001 0.117 0.324 0.72
Situated in northern China 20.008 0.085 0.93 20.282 0.262 0.30
GRP
I: per US$100 0.009 0.003 0.001 0.013 0.007 0.10
First order interactions
Severe GCS score on admission x assisted feeding 0.269 0.106 0.01 - - -
In-hospital complication x disability/dependency 20.121 0.052 0.02 - - -
Length of stay x married 20.137 0.059 0.03 - - -
Length of stay x large hospital size 20.216 0.065 0.002 - - -
Large hospital size x teaching hospital 0.459 0.109 ,0.001 - - -
Health insurance x GRP
I 20.003 0.001 0.03 - - -
Health insurance x income 10,000 – 19,999 CNY - - - 0.264 0.116 0.04
GRP
I x income 10,000 – 19,999 CNY 20.008 0.002 ,0.001 - - -
GRP
I x income $20,000 CNY 20.006 0.002 0.005 - - -
*Model outcome is log transformed, unit is US$100.
{Reference group: annual household income # 9,999 CNY (< US$1,428).
{Reference group: small artery lacunar infarct; Other/uncertain category includes: cardioembolic, retinal, venous and other defined infarcts, infarcts of unknown cause
and stroke of uncertain pathological type.
1Variable were further log transformed before regression.
I2006 per capita gross regional product for province in which hospital is located.
doi:10.1371/journal.pone.0013041.t002
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subject to recall and interview bias, but given the standardised
approach to data collection, we do not anticipate this to have been
a major issue. Indeed, non-response to the cost item was only 1%
among survivors in the study. In addition, the effect of recall or
‘social desirability’ bias is also expected to be minimal given the
fee-for-service nature of the health care system in China, such that
all costs are invoiced to patient or nominated family member.
Although different methods of interview administration (face-to-
face vs. telephone) were employed for our participant surveys,
previous research has indicated that while each approach may
engender some degree of social acceptability bias, the difference
between modes is likely to be small [45] and the reliability of
reported health behaviours high regardless of interview mode [46].
Finally, although we may have included the costs associated with
early re-admission to hospital in our estimates, sensitivity analyses
revealed minimal effect of excluding such patients, and the
consistency of our findings with national estimates and other
studies in China, provides reassurance to the validity of these data.
In summary, this study provides estimates of the current hospital
costs of acute stroke care in China, and of the factors that
determine variation in these costs. The LOS in hospital and
background economic situation of the patient, defined either by
the possession of health insurance or amount of household income,
are key drivers of these health care costs, as shown in other
countries with fee-for-service funding schemes. Reductions in
hospital costs could result from new operational policies that
include clinical pathways and standardised use of resources,
coupled with improved physician training and the introduction of
new models of care to reduce LOS, but this will need confirmation
in future research. Our study suggests that there is scope to
improve efficiencies in the management of patients with stroke
through reducing LOS in some hospitals. Nevertheless, any such
changes can only be sustained through broader policy develop-
ment, such as those being tested in recent initiatives to introduce
case-based funding and in pilot studies to reform payment systems
to address misalignment of incentives and encourage appropriate
treatment. Given the projected increase in the number of patients
with stroke associated with the rapid aging of the population,
efforts to improve the efficiency of hospitals and community
services are needed at the individual hospital level but also, and
arguably more importantly, through effective policies that enable
reform across the entire health system.
Supporting Information
Table S1 Baseline characteristics of patients*. *Values are
reported as mean6SD, median (IQR), or number (percentage)
of subjects; percentages are based on non-missing values. {Defined
as $2 of the following: history of hypertension, diabetes,
hyperlipidaemia, atrial fibrillation; prior stroke, prior transient
ischaemic attack, prior coronary artery disease, cigarette smoking,
regular alcohol consumption, and being overweight (body mass
index $24 kg/m2 [31]). {Other/Uncertain category includes:
cardioembolic, retinal, venous and other defined infarcts, infarcts
of unknown cause and stroke of uncertain pathological type.
IGCS, Glasgow Coma Scale, severe score #8 in range 3 (low) to
15 (high, normal). #Disability/dependence defined as modified
Rankin Scale (mRS) score between 3–5. **2006 per capita gross
regional product for province in which hospital is located; to
convert to US$, divide by 7.
Found at: doi:10.1371/journal.pone.0013041.s001 (0.05 MB
DOC)
Acknowledgments
We sincerely thank all the patients and their families for their co-operation
in participating in the study; and the hospital, scientific, data management,
and statistical staff associated with the study. We are also exceedingly
grateful to the statistical advice provided by various statisticians at The
George Institute including Serigne Lo, Qiang Li, Laurent Billot, Stephane
Heritier, and Mark Woodward.
Author Contributions
Conceived and designed the experiments: JWW YH CA. Analyzed the
data: JWW EH SJ CA. Wrote the paper: JWW. Collected data for the
study: EH YH QH J-GW YC EX QY. Contributed to writing the paper:
EH SJ J-GW CA. Enrolled patients for the study: YH QH J-GW YC EX
QY.
Table 3. Predicted cost of stroke by stroke type and modifiable variables for Level 2 and 3 hospitals*.
Variable Small artery lacunar infarct Large artery cerebral infarct Intracerebral haemorrhage
Predicted cost
(CNY)
Potential saving
{
(CNY)
Predicted cost
(CNY)
Potential saving
{
(CNY) Predicted cost (CNY)
Potential
saving
{
(CNY)
Level 3 hospital
Experienced $1 in-hospital
complication
12,005 2,156 16,227 2,913 14,721 2,643
Disability/dependency at discharge 12,189 2,715 15,463 3,444 14,226 3,169
Length of stay: mean
{ vs. 7 days 10,958 5,069 15,325 7,942 14,061 7,606
Non-teaching hospital 15,667 6,179 22,338 8,810 19,819 7,817
Level 2 hospital
Disability/dependency at discharge 6,931 1,489 7,154 1,537 8,299 1,783
Length of stay : mean vs. 7 days 6,076 1,042 6,799 1,283 7,956 1,779
*To convert CNY to US dollars, divide by 7.
{For in-hospital complication, disability/dependency and non-teaching hospital: potential saving=predicted cost for average person with variable – predicted cost for
average person if variable was removed, holding all variables constant at their means; for length of stay: potential saving = predicted cost for average person with
mean length of stay – predicted cost for average person if length of stay was reduced to 7 days, holding all variables constant at their means.
{19 days, 22 days, and 24 days for small artery lacunar infarct, large artery cerebral infarct, and intracerebral haemorrhage patients, respectively in Level 3 hospital.
116 days, 18 days, and 21 days for small artery lacunar infarct, large artery cerebral infarct, and intracerebral haemorrhage patients, respectively in Level 2 hospital.
doi:10.1371/journal.pone.0013041.t003
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